Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Avenue Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q1 2022
- Shares held
- 674.6K
- −367.6K (−35.3%) vs. Q1 2022
- Total value
- $181.0K
- −$322.0K (−64.0%) vs. Q1 2022
- New holders
- 6
- 2 more added
- Sold out
- 4
- 8 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATXI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 7 | $385.3K |
| Q3 2024 | 8 | $491.8K |
| Q2 2024 | 9 | $407.2K |
| Q1 2024 | 14 | $168.9K |
| Q4 2023 | 15 | $52.4K |
| Q3 2023 | 14 | $157.3K |
| Q2 2023 | 12 | $849.4K |
| Q1 2023 | 14 | $532.7K |
| Q4 2022 | 14 | $520.5K |
| Q3 2022 | 11 | $766.0K |
| Q2 2022 | 19 | $181.0K |
| Q1 2022 | 17 | $503.0K |
| Q4 2021 | 18 | $2.14M |
| Q3 2021 | 21 | $1.62M |
| Q2 2021 | 29 | $2.88M |
| Q1 2021 | 34 | $11.1M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Avenue Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 131,569 | $36.0K | 0.00% | −321,084−70.9% | Reduced |
| Renaissance Technologies LLC | 124,400 | $34.0K | 0.00% | +124,400 | New |
| Geode Capital Management, LLC | 84,033 | $22.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 68,067 | $18.0K | 0.00% | +20,005+41.6% | Added |
| National Asset Management, Inc. | 58,330 | $16.0K | 0.00% | −2,000−3.3% | Reduced |
| HRT Financial LP | 39,100 | $10.0K | 0.00% | +39,100 | New |
| UBS Group AG | 31,843 | $9.00K | 0.00% | +859+2.8% | Added |
| BlackRock Inc. | 29,183 | $7.00K | 0.00% | −25,696−46.8% | Reduced |
| Two Sigma Securities, LLC | 26,156 | $7.00K | 0.00% | −26,657−50.5% | Reduced |
| Susquehanna International Group, LLP | 25,707 | $7.00K | 0.00% | +25,707 | New |
| Emfo, LLC | 16,000 | $4.00K | 0.00% | −8,000−33.3% | Reduced |
| Northern Trust Corp | 13,767 | $4.00K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 11,247 | $3.00K | 0.00% | −381−3.3% | Reduced |
| Cetera Advisor Networks LLC | 11,392 | $3.00K | 0.00% | +11,392 | New |
| Tower Research Capital LLC (TRC) | 3,135 | $1.00K | 0.00% | −28,933−90.2% | Reduced |
| BNP Paribas Arbitrage, SA | 8 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 132 | $0 | 0.00% | −43−24.6% | Reduced |
| JPMorgan Chase & Co | 1 | $0 | 0.00% | +1 | New |
| Citigroup Inc | 500 | $0 | 0.00% | +500 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −117,674−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −58,004−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −104−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,002−100.0% | Sold out |